Fuxman Claudia, Sicilia Beatriz, Linares María Eugenia, García-López Santiago, González Sueyro Ramiro, González-Lamac Yago, Zabana Yamile, Hinojosa Joaquín, Barreiro-de Acosta Manuel, Balderramo Domingo, Balfour Deborah, Bellicoso Maricel, Daffra Pamela, Morelli Daniela, Orsi Marina, Rausch Astrid, Ruffinengo Orlando, Toro Martín, Sambuelli Alicia, Novillo Abel, Gomollón Fernando, De Paula Juan Andrés
Servicio de Gastroenterología, Hospital Universitario Fundación Favaloro, Buenos Aires, Argentina.
Unidad de Enfermedad Inflamatoria Intestinal, Servicio de Aparato Digestivo, Hospital Universitario de Burgos, Burgos, España.
Gastroenterol Hepatol. 2023 Mar;46 Suppl 1:S1-S56. doi: 10.1016/j.gastrohep.2023.01.009. Epub 2023 Jan 31.
Ulcerative colitis (UC) is a chronic inflammatory disease that compromises the colon, affecting the quality of life of individuals of any age. In practice, there is a wide spectrum of clinical situations. The advances made in the physio pathogenesis of UC have allowed the development of new, more effective and safer therapeutic agents.
To update and expand the evaluation of the efficacy and safety of relevant treatments for remission induction and maintenance after a mild, moderate or severe flare of UC.
Gastroenterologists, coloproctologists, general practitioners, family physicians and others health professionals, interested in the treatment of UC.
GADECCU authorities obtained authorization from GETECCU to adapt and update the GETECCU 2020 Guide for the treatment of UC. Prepared with GRADE methodology. A team was formed that included authors, a panel of experts, a nurse and a patient, methodological experts, and external reviewers. GRADE methodology was used with the new information.
A 118-page document was prepared with the 44 GADECCU 2022 recommendations, for different clinical situations and therapeutic options, according to levels of evidence. A section was added with the new molecules that are about to be available.
This guideline has been made in order to facilitate decision-making regarding the treatment of UC, adapting and updating the guide prepared by GETECCU in the year 2020.
溃疡性结肠炎(UC)是一种慢性炎症性疾病,会累及结肠,影响各年龄段人群的生活质量。在实际临床中,存在广泛的临床情况。UC生理发病机制方面的进展使得新型、更有效且更安全的治疗药物得以研发。
更新并扩展对UC轻、中、重度发作后诱导缓解和维持缓解相关治疗的疗效及安全性评估。
对UC治疗感兴趣的胃肠病学家、结直肠外科医生、全科医生、家庭医生及其他医疗专业人员。
GADECCU机构获得GETECCU授权,对GETECCU 2020年UC治疗指南进行改编和更新。采用GRADE方法编写。组建了一个团队,成员包括作者、专家小组、一名护士、一名患者、方法学专家及外部评审员。使用新信息采用GRADE方法。
根据证据水平,针对不同临床情况和治疗选择,编写了一份包含44条GADECCU 2022建议的118页文件。增加了一部分关于即将上市的新分子的内容。
本指南旨在促进UC治疗决策,改编并更新了GETECCU在2020年编写的指南。